Veracyte | VCYT - Selling And Administration Expenses


Veracyte reported $43.31M in Selling and Administration Expenses for its fiscal quarter ending in December of 2025.





Selling And Administration Expenses Change Date
Agenus USD 10.56M 13.04M Dec/2025
Agilent USD 476M 48M Dec/2025
Anika Therapeutics USD 10.01M 14K Dec/2025
Arrowhead Research USD 46.02M 8.84M Dec/2025
Bruker USD 247.2M 4.7M Dec/2025
Heron Therapeutics USD 23.74M 605K Dec/2025
Illumina USD 283M 27M Dec/2025
Intrexon USD 10.31M 41K Jun/2024
Karyopharm Therapeutics USD 9.56M 17.63M Dec/2025
Laboratory Of America USD 538.6M 13.8M Dec/2025
Ligand Pharmaceuticals USD 28.45M 8.27M Sep/2025
Myriad Genetics USD 122.3M 6.7M Dec/2025
Rigel Pharmaceuticals USD 27.04M 1M Sep/2024
Roche Holding CHF 7.28B 3.99B Dec/2025
Sangamo BioSciences USD 9.64M 1.83M Jun/2024
Siemens EUR 3.61B 489M Dec/2025
Sonic Healthcare AUD 2.52B 2.46B Dec/2024
Thermo Fisher Scientific USD 1.98B 182M Dec/2025
Veracyte USD 43.31M 8.43M Dec/2025
Waters USD 240.01M 25.78M Dec/2025